Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513652 | 0.85 | TYK2 (0.50) | TYK2L3MBTL1TP53ALDH1A1TSHR | |
| SCHEMBL4591180 | 0.82 | TYK2 (0.62) | TYK2DAPK3PIM1PIM3L3MBTL1 | |
| SCHEMBL4513761 | 0.81 | PDE9A (0.49) | — | |
| SCHEMBL4524313 | 0.78 | TYK2 (0.45) | TYK2L3MBTL1TP53ALDH1A1TSHR | |
| SCHEMBL17506173 | 0.76 | TYK2 (0.57) | TYK2DAPK3PIM1PIM3L3MBTL1 | |
| SCHEMBL4510202 | 0.75 | TYK2 (0.58) | TYK2DAPK3PIM1PIM3L3MBTL1 | |
| SCHEMBL4498181 | 0.75 | TYK2 (0.56) | TYK2DAPK3PIM1PIM3L3MBTL1 | |
| SCHEMBL4510380 | 0.75 | TYK2 (0.53) | TYK2DAPK3PIM1PIM3L3MBTL1 | |
| SCHEMBL4510623 | 0.74 | TYK2 (0.55) | TYK2DAPK3PIM1PIM3L3MBTL1 | |
| SCHEMBL4512357 | 0.74 | KMT2A (0.53) | TYK2L3MBTL1TP53ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | TYK2 3816/4885DAPK3 648/4885PIM1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.